ALNY - Company ID 0001178670
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported net income of $313.75M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $313.75M | +212.8% |
| FY 2024 | -$278.16M | +36.8% |
| FY 2023 | -$440.24M | +61.1% |
| FY 2022 | -$1.13B | -32.6% |
| FY 2021 | -$852.82M | +0.6% |
| FY 2020 | -$858.28M | +3.1% |
| FY 2019 | -$886.12M | -16.4% |
| FY 2018 | -$761.50M | -55.1% |
| FY 2017 |
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported net income of $313.75M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ALNYLAM PHARMACEUTICALS, INC.'s net income grew from -$57.65M to $313.75M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$490.87M |
| -19.7% |
| FY 2016 | -$410.11M | -41.4% |
| FY 2015 | -$290.07M | +19.5% |
| FY 2014 | -$360.39M | -303.9% |
| FY 2013 | -$89.22M | +15.8% |
| FY 2012 | -$106.01M | -83.9% |
| FY 2011 | -$57.65M | - |